Based in Scottsdale, Arizona, Darwin Research Group has spent over a decade producing primary intelligence that helps life sciences companies navigate one of the most consequential shifts in modern healthcare: the rise of organized systems of care.Continue reading
Up to 15 companies will be selected from the applicant pool to take part in each cohort anchored around key activities in the state. The Fall 2026 Cohort will focus on biotech and health tech and will coincide with Arizona Bioscience Week, kicking off on October 5, 2026. Applications close August 7, 2026.Continue reading
On June 16, 2026, Senate Finance Committee Ranking Member Ron Wyden (D-OR) released a request for information on a host of proposals aimed at lowering the cost of prescription drugs, as a part of Senate Democrats’ work to make health care affordable for all Americans. Text of the Request for Information (PDF) Members of the public are encouraged to weigh in with feedback by August 17, 2026.
The request for information focuses on three policy objectives:
Global contract research organization specializing in translational oncology brings its preclinical model and biomarker capabilities to the coalition’s work advancing the adoption and qualification of new approach methodologies.Continue reading
TUCSON, AZ, July 15, 2026 — NuvOx Therapeutics, Inc. (“NuvOx Therapeutics”, “NuvOx”, or the “Company”) today announces that its wholly owned subsidiary, NuvOx Pharma LLC, has been granted Fast Track designation for NanO₂™ by the U.S. Food and Drug Administration (“FDA”) for the treatment of adult patients presenting with acute ischemic stroke (“AIS”).
BioCentury co-founder succeeds Wain Fishburn, effective July 1Continue reading
Fusion antibody was comparable to aducanumab treatment in clearing amyloid plaques in mice
Based in Phoenix, Arizona, TGen’s mission is to translate research discoveries into improved diagnostics and therapies, shortening the path from scientific discovery to improved patient outcomes.Continue reading
TGen-led study clarifies interactions between amyloid, tau, alpha-synuclein proteins